World Journal of Hepatology - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

JOURNAL HOME

Number of total visits: 2816118

Number of visits today: 628

Number of downloads: 2065786

MEMBERSHIP

BPG JOURNALS

Cited by in F6Publishing

For:	Luo M, Xiong Y, Lin Y, Liang R, Li Y, Ge L. H Long Terminal Repeat-Associating 2 (HHLA2) is a Biomarker of Advanced Stage Hepatocellular Carcinoma and Promotes Tumor Cell Development In Vitro. Med Sci Monit 2021;27:e930215. [PMID: 33990536 DOI: 10.12659/MSM.930215] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]

For:

Luo M, Xiong Y, Lin Y, Liang R, Li Y, Ge L. H Long Terminal Repeat-Associating 2 (HHLA2) is a Biomarker of Advanced Stage Hepatocellular Carcinoma and Promotes Tumor Cell Development In Vitro. Med Sci Monit 2021;27:e930215. [PMID: 33990536 DOI: 10.12659/MSM.930215] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]

Number	Citing Articles
1	Chi H, Zhao S, Yang J, Gao X, Peng G, Zhang J, Xie X, Song G, Xu K, Xia Z, Chen S, Zhao J. T-cell exhaustion signatures characterize the immune landscape and predict HCC prognosis via integrating single-cell RNA-seq and bulk RNA-sequencing. Front Immunol 2023;14. [DOI: 10.3389/fimmu.2023.1137025] [Reference Citation Analysis]
2	Ahangar NK, Khalaj-Kondori M, Alizadeh N, Mokhtarzadeh A, Baghbanzadeh A, Shadbad MA, Dolatkhah K, Baradaran B. Silencing tumor-intrinsic HHLA2 potentiates the anti-tumoral effect of paclitaxel on MG63 cells: Another side of immune checkpoint. Gene 2023;855:147086. [PMID: 36535461 DOI: 10.1016/j.gene.2022.147086] [Reference Citation Analysis]
3	Li Y, Lv C, Yu Y, Wu B, Zhang Y, Lang Q, Liang Z, Zhong C, Shi Y, Han S, Xu F, Tian Y. KIR3DL3-HHLA2 and TMIGD2-HHLA2 pathways: The dual role of HHLA2 in immune responses and its potential therapeutic approach for cancer immunotherapy. J Adv Res 2022:S2090-1232(22)00167-9. [PMID: 35933091 DOI: 10.1016/j.jare.2022.07.013] [Reference Citation Analysis]
4	Ying H, Xu J, Zhang X, Liang T, Bai X. Human endogenous retrovirus-H long terminal repeat-associating 2: The next immune checkpoint for antitumour therapy. eBioMedicine 2022;79:103987. [DOI: 10.1016/j.ebiom.2022.103987] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5	Niu Y, Huang Y, Dong A, Sun Y. Human Endogenous Retrovirus-H Long Terminal Repeat-Associating Protein 2 Possesses Prognostic Significance and Promotes Progression of Papillary Thyroid Cancer. IJGM 2022;Volume 15:1509-16. [DOI: 10.2147/ijgm.s338564] [Reference Citation Analysis]
6	Luo M, Lin Y, Liang R, Li Y, Ge L. Clinical Significance of the HHLA2 Protein in Hepatocellular Carcinoma and the Tumor Microenvironment. J Inflamm Res 2021;14:4217-28. [PMID: 34483677 DOI: 10.2147/JIR.S324336] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]